Keros Therapeutics, Inc. (KROS)
16.20
-0.35
(-2.11%)
USD |
NASDAQ |
Feb 20, 16:00
16.21
+0.01
(+0.06%)
After-Hours: 20:00
Keros Therapeutics SG&A Expense (Quarterly) : 10.13M for Sept. 30, 2025
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Amicus Therapeutics, Inc. | 117.08M |
| MannKind Corp. | 58.18M |
| Sarepta Therapeutics, Inc. | 91.89M |
| Insmed, Inc. | 212.48M |
| Ionis Pharmaceuticals, Inc. | 96.81M |